Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2018 Filed Sep 7, 2018 18:41 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000035 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:32 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-18-000017 · edgar.xml · derivative · entry 3 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2028-09-04 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:32 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000017 · edgar.xml · derivative · entry 2 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:25 UTC |
TUMOLO ANNETTEExecutive Vice President
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-18-000019 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2028-09-04 F4 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:25 UTC |
TUMOLO ANNETTEExecutive Vice President
|
GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000019 · edgar.xml · derivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:29 UTC |
STARK JAMES RVP, Corporate Controller
|
GrantRestricted Stock Units · Derivative | 1,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000015 · edgar.xml · derivative · entry 2 STARK JAMES R · CIK 0001248083 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:19 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-18-000011 · edgar.xml · derivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires 2028-09-04 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:19 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
GrantRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000011 · edgar.xml · derivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:25 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-18-000013 · edgar.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Bio-Rad A Common Stock · 13,000 shares Expires 2028-09-04 F5 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:25 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GrantRestricted Stock Units · Derivative | 13,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000013 · edgar.xml · derivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Bio-Rad A Common Stock · 13,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:13 UTC |
HUTTON RONALD WVice President and Treasurer
|
GrantRestricted Stock Units · Derivative | 900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000009 · edgar.xml · derivative · entry 2 HUTTON RONALD W · CIK 0001248073 · Vice President and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Underlying: Bio-Rad A Common Stock · 900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:08 UTC |
HERTIA JOHNExecutive Vice President
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-18-000007 · edgar.xml · derivative · entry 4 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2028-09-04 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:08 UTC |
HERTIA JOHNExecutive Vice President
|
GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000007 · edgar.xml · derivative · entry 3 HERTIA JOHN · CIK 0001616003 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 18:58 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-18-000004 · edgar.xml · derivative · entry 3 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires 2028-09-04 F4 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 18:58 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
GrantRestricted Stock Units · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000004 · edgar.xml · derivative · entry 2 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Bio-Rad A Common Stock · 2,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 18:54 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $326.15 | $0.00 |
DisclosureSEC source: 0001652252-18-000002 · edgar.xml · derivative · entry 3 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2028-09-04 F3 · derivative.exercise_date: The stock option vests over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 18:54 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
GrantRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001652252-18-000002 · edgar.xml · derivative · entry 2 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over five years at 20% per year on the yearly anniversary date of the grant. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 17:23 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 350 | $303.42 | $106,197.14 |
DisclosureSEC source: 0001315406-18-000008 · edgar.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,142 Read SEC document |
| May 11, 2018 Filed May 12, 2018 00:47 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $88.48 | $0.00 |
DisclosureSEC source: 0001315406-18-000006 · edgar.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 37,500 shares Expires 2018-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning on June 11, 2009. Read SEC document |
| May 11, 2018 Filed May 12, 2018 00:47 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President and CEO · 10% owner
|
Tax withholdingBio-Rad B Common Stock | 24,273 | $284.98 | $6,917,319.54 |
DisclosureSEC source: 0001315406-18-000006 · edgar.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,145 Read SEC document |
| May 11, 2018 Filed May 12, 2018 00:47 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President and CEO · 10% owner
|
Exercise / conversionBio-Rad B Common Stock | 37,500 | $88.48 | $3,318,000.00 |
DisclosureSEC source: 0001315406-18-000006 · edgar.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2018 Filed May 12, 2018 00:41 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.00 | $0.00 |
DisclosureSEC source: 0001315406-18-000004 · edgar.xml · derivative · entry 3 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,500 shares Expires 2018-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested in five equal annual installments beginning on June 11, 2009. Read SEC document |
| May 11, 2018 Filed May 12, 2018 00:41 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Tax withholdingBio-Rad A Common Stock | 1,918 | $284.98 | $546,591.64 |
DisclosureSEC source: 0001315406-18-000004 · edgar.xml · nonDerivative · entry 2 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,833 Read SEC document |
| May 11, 2018 Filed May 12, 2018 00:41 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionBio-Rad A Common Stock | 3,500 | $88.00 | $308,000.00 |
DisclosureSEC source: 0001315406-18-000004 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · derivative · entry 11 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested in five equal annual installments beginning September 11, 2016. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $119.54 | $0.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · derivative · entry 10 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: Bio-Rad A Common Stock · 800 shares Expires 2024-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested in five equal annual installments beginning September 10, 2015. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,280 | $0.00 Strike: $117.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · derivative · entry 9 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640 Underlying: Bio-Rad A Common Stock · 1,280 shares Expires 2023-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in five equal annual installments beginning September 11, 2014. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,300 | $0.00 Strike: $107.32 | $0.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · derivative · entry 8 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 1,300 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in five equal annual installments beginning September 12, 2013 Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 600 | $0.00 Strike: $98.04 | $0.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · derivative · entry 7 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires 2021-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in five equal annual installments beginning November 4, 2012. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
SaleBio-Rad A Common Stock | 4,980 | $249.40 | $1,242,019.97 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · nonDerivative · entry 6 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,683.0979 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $249.15 to $249.54, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionBio-Rad A Common Stock | 1,000 | $139.56 | $139,560.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · nonDerivative · entry 5 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,663.0979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionBio-Rad A Common Stock | 800 | $119.54 | $95,632.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · nonDerivative · entry 4 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,663.0979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionBio-Rad A Common Stock | 1,280 | $117.00 | $149,760.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · nonDerivative · entry 3 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,863.0979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionBio-Rad A Common Stock | 1,300 | $107.32 | $139,516.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · nonDerivative · entry 2 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,583.0979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 00:26 UTC |
TSINGOS CHRISTINE AEVP and CFO
|
Exercise / conversionBio-Rad A Common Stock | 600 | $98.04 | $58,824.00 |
DisclosureSEC source: 0001652252-17-000116 · edgar.xml · nonDerivative · entry 1 TSINGOS CHRISTINE A · CIK 0001278861 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,283.0979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2017 Filed Dec 28, 2017 17:22 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 53 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-17-000022 · edgar.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,717 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 05, 2017 Filed Dec 28, 2017 17:22 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 53 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-17-000022 · edgar.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,918 Read SEC document |
| December 05, 2017 Filed Dec 28, 2017 17:05 UTC |
SCHWARTZ ALICE NDirector · 10% owner
|
GiftBio-Rad B Common Stock | 318 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-17-000020 · edgar.xml · nonDerivative · entry 6 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 439,244 Read SEC document |
| December 05, 2017 Filed Jan 9, 2018 19:15 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 53 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-18-000002 · edgar.xml · nonDerivative · entry 4 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,717 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 05, 2017 Filed Jan 9, 2018 19:15 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 53 | $0.00 | $0.00 |
DisclosureSEC source: 0001315406-18-000002 · edgar.xml · nonDerivative · entry 3 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,945 Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 00:36 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 1,000 | $258.39 | $258,394.70 |
DisclosureSEC source: 0001315406-17-000018 · edgar.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,492 Read SEC document |
| November 30, 2017 Filed Nov 30, 2017 23:52 UTC |
STARK JAMES RVP, Corporate Controller
|
SaleBio-Rad A Common Stock | 746 | $270.51 | $201,797.70 |
DisclosureSEC source: 0001652252-17-000114 · edgar.xml · nonDerivative · entry 1 STARK JAMES R · CIK 0001248083 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 14, 2017 Filed Nov 15, 2017 22:04 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
SaleBio-Rad A Common Stock | 2,400 | $253.01 | $607,225.68 |
DisclosureSEC source: 0001652252-17-000112 · edgar.xml · nonDerivative · entry 1 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,251 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.00 to $253.10, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 00:27 UTC |
Hall ShannonExecutive Vice President
|
SaleBio-Rad A Common Stock | 1,245 | $221.20 | $275,390.14 |
DisclosureSEC source: 0001652252-17-000108 · edgar.xml · nonDerivative · entry 1 Hall Shannon · CIK 0001621222 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564.5691 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.18 to 221.24, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:26 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,600 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001652252-17-000106 · edgar.xml · derivative · entry 15 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Underlying: Bio-Rad A Common Stock · 1,600 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in five equal annual installments beginning September 7, 2017. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:26 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,600 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001652252-17-000106 · edgar.xml · derivative · entry 14 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Bio-Rad A Common Stock · 1,600 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:26 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $119.54 | $0.00 |
DisclosureSEC source: 0001652252-17-000106 · edgar.xml · derivative · entry 13 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Bio-Rad A Common Stock · 1,200 shares Expires 2024-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in five equal annual installments beginning September 10, 2015. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:26 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 640 | $0.00 Strike: $117.00 | $0.00 |
DisclosureSEC source: 0001652252-17-000106 · edgar.xml · derivative · entry 12 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640 Underlying: Bio-Rad A Common Stock · 640 shares Expires 2023-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in five equal annual installments beginning September 11, 2014. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:26 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 650 | $0.00 Strike: $107.32 | $0.00 |
DisclosureSEC source: 0001652252-17-000106 · edgar.xml · derivative · entry 11 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 650 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests in five equal annual installments beginning September 12, 2013. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:26 UTC |
GOETZ JOHNEVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 1,388 | $220.47 | $306,012.36 |
DisclosureSEC source: 0001652252-17-000106 · edgar.xml · nonDerivative · entry 10 GOETZ JOHN · CIK 0001237945 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,473.3235 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.